Behind the re-emergence of the "departure tide" of multinational pharmaceutical companies, the domestic pharmaceutical market is surging

Recently, it was reported that Luo Yongqing, general manager of Gilead China, has confirmed his departure on September 10.
Will be in charge of the China team and business on an interim until the new general manager is called in after September 10.
According to the company's public information, Luo Yongqing joined Gilead in 2016 and is currently the company's global vice president and general manager of China, responsible for the establishment and operation of the company in the Chinese market, dedicated to the introduction of hepatitis B, hepatitis C, AIDS and other diseases to China for the benefit of Chinese patients.
also recognized Luo Yongqing's contribution: from the establishment of Gilead Science's Chinese team and the company's commercial operations, to the rapid approval and listing of eight innovative drugs in the Chinese market, four of which were listed in the national health insurance list within a year.
, Gilead Science China has become an important pillar of the company's global development strategy.
, in fact, in addition to Gilead China, there have been a number of personnel changes in the senior management of multinational pharmaceutical companies so far this year.
, for example, in June, Duan Xiaoxuan, the former president and CEO of GE International, who had been in charge of China for six years, announced his resignation.
, Guo Anfeng, a former vice president of BMS Oncology, left his post to join 1 Pharmaceutical Network as Chief Innovation Officer, fully responsible for the company's Internet medical platform operations and innovation.
April, Huang Weidong, President of Bayer CropScience Greater China, joined Yiteng Pharmaceuticals as Chief Operating Officer, fully responsible for the commercial operation of Yiteng Pharmaceutical Group.
, Mu Yanping, the former head of Merca East's China Oncology Division, resigned and joined Shanghai Allis Pharmaceuticals as CEO, fully responsible for the company's business operations.
in the industry's view, multinational pharmaceutical companies are often "departure tide" behind, is the domestic pharmaceutical market surge, the industry reshuffle is intensifying.
in the third round of collection, which ended recently, a total of 189 enterprises participated, resulting in 125 enterprises to be selected, 191 to choose the drug product regulations, the average price reduction of 53%, to a high drop of 95%.
And multinational pharmaceutical companies appear a collective "great retreat" phenomenon, many enterprises because the price exceeds the highest effective declared price and early exit, and a small number of enterprises symbolically choose to reduce prices by about 10%, almost equivalent to giving up the collection market directly.
the normalization of drug collection, the performance of some multinational pharmaceutical companies has been affected to some.
, such as Sanofi and Pfizer, saw their performance in China fall by more than 10% in the first half of 2020.
Among them, Pfizer's first-half results in China fell 21%, and Lipto (Atovastatin) and Lysin Hi (ammonia chloride) were eliminated in the "4-plus-7" volume purchase and "4-plus-7" expansion, which resulted in a decline in sales in the second quarter of 2019.
industry believes that domestic generic drugs have entered the era of micro-profits, which will force multinational pharmaceutical companies to seek business transformation, focusing on new drug research and development innovation.
at the same time, will bring a series of personnel adjustments, the future or trigger the Chinese pharmaceutical market talent war, and the cooperation and competition between local pharmaceutical companies will be more intense.
as for Mr Luo's next move, most executives at multinational pharmaceutical companies have generally chosen local innovative pharmaceutical companies after leaving their jobs.
in terms of Luo Yongqing's previous professional experience, mostly focused on Novarth, Roche and other large multinational pharmaceutical companies, but the specific choice after leaving office will be where, everything needs to be announced on September 10th.